Goldline Pharmaceutical Share Price Plunges 5% as Trading Halted Due to Circuit Breaker
Goldline Pharmaceutical
IPOGoldline Pharmaceutical Makes Strong Debut on BSE SME
Today, Goldline Pharmaceutical marked a notable debut on the BSE SME, with its share price opening at ₹59.75, a 40% increase from the issue price of ₹43. Following a successful listing, the stock was locked in at a 5% lower circuit at ₹56.77 per share. The intraday high of ₹60 per share further underscored the company's strong market performance.
The initial public offering (IPO) of Goldline Pharmaceuticals, which opened for subscription on Tuesday, 12 May, will close on Thursday, 14 May. The company has set the price band for the issue at ₹41–₹43 per equity share, with a face value of ₹10 per equity share. Notably, the IPO subscription status was 600.53x on day 3, according to chittorgarh.com.
Investors can apply for a minimum lot size of 3,000 equity shares, with subsequent applications in multiples of 3,000 shares. Goldline Pharmaceuticals focuses on promoting pharmaceutical products under its main "Goldline" brand, offering a diverse range of products across different therapeutic areas. The business is segmented into five primary divisions: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness.
Read also: SMR Jewels IPO Successfully Lists with Institutional Support
The company's product range addresses numerous medical specialties, including orthopaedics, gastroenterology, neurology, cardiology, endocrinology, paediatrics, neonatal care, critical care, and supportive oncology treatment.
IPO Details
| IPO Details | Value |
|---|---|
| IPO Value | ₹11.61 crore |
| Fresh Issue | 27 lakh shares |
| Primary Purpose | Settle ₹8.35 crore in loans, general corporate purposes |
| Total Debt (as of March 2026) | ₹9.13 crore |
The IPO is being managed by Cumulative Capital Pvt. Ltd as the book-running lead manager, with Bigshare Services Pvt. Ltd serving as the registrar and Nirman Share Brokers Pvt. Ltd appointed as the market maker.
Grey Market Premium Goldline Pharmaceutical's IPO GMP today is +15, indicating a readiness among investors to pay more than the issue price. Considering the upper end of the IPO price band and the current premium in the grey market, the estimated listing price of Goldline Pharmaceutical share price was indicated at ₹58 apiece, which is 34.88% higher than the IPO price of ₹43.
Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO
Investor Takeaway
Investors should be cautious of the stock's performance after the circuit breaker.
More in IPO
SMR Jewels IPO Successfully Lists with Institutional Support
Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO
Merritronix IPO Sees Robust Subscription, Oversubscribed by 293 Times on Final Day
